SY   MelHOrDAC20; Mel-HOrDAC20
DR   cancercelllines; CVCL_RQ54
DR   Wikidata; Q54905179
RX   PubMed=22170099;
CC   Problematic cell line: Misidentified/contaminated. Parent cell line (Mel-Ho) was reported to be isogenic with LCL-Ho (Cellosaurus=CVCL_1868) but it does not have the same STR profile.
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; (5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide)).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1402 ! Mel Ho
SX   Female
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 9
RX   PubMed=22170099; DOI=10.1038/cddis.2011.129;
RA   Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M.,
RA   Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F.,
RA   Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D.,
RA   Cinatl J. Jr.;
RT   "Adaptation of cancer cells from different entities to the MDM2
RT   inhibitor nutlin-3 results in the emergence of p53-mutated
RT   multi-drug-resistant cancer cells.";
RL   Cell Death Dis. 2:e243.1-e243.8(2011).